▲ 7.26%
prev close
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
+1
1 buys · 0 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-11-21 | GHGuardant Health, Inc. | Buy | $1,001 - $15,000 | 139d ago | — |
2025-11-21
Sheldon Whitehouse
GH
Amount
$1,001 - $15,000
Filed
139d ago
Recent News
Powered by Polygon.io
Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line
Trade Timeline
Congressional activity, newest first
Sheldon Whitehouse
2025-11-21 · Purchase
$1,001 - $15,000